Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Retained Earnings: 2022-2025

Historic Retained Earnings for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to -$640.1 million.

  • Day One Biopharmaceuticals' Retained Earnings fell 31.07% to -$640.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$640.1 million, marking a year-over-year decrease of 31.07%. This contributed to the annual value of -$554.1 million for FY2024, which is 20.82% down from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Retained Earnings stood at -$640.1 million for Q3 2025, which was down 3.18% from -$620.4 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Retained Earnings high stood at -$155.2 million for Q1 2022, and its period low was -$640.1 million during Q3 2025.
  • Over the past 3 years, Day One Biopharmaceuticals' median Retained Earnings value was -$521.0 million (recorded in 2024), while the average stood at -$497.5 million.
  • Data for Day One Biopharmaceuticals' Retained Earnings shows a maximum YoY crashed of 101.03% (in 2023) over the last 5 years.
  • Over the past 4 years, Day One Biopharmaceuticals' Retained Earnings (Quarterly) stood at -$269.7 million in 2022, then crashed by 70.06% to -$458.6 million in 2023, then declined by 20.82% to -$554.1 million in 2024, then tumbled by 31.07% to -$640.1 million in 2025.
  • Its Retained Earnings stands at -$640.1 million for Q3 2025, versus -$620.4 million for Q2 2025 and -$590.1 million for Q1 2025.